Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.
Post-doctoral researchers awarded a three-year fellowship will have access to Yale’s robust computational resources, biomedical data repositories and faculty expertise. In addition, they will benefit from access to Boehringer Ingelheim’s corporate labs, scientists and executives. Applicants are invited to submit research proposals for consideration by June 15. If approved for a fellowship, they will be jointly mentored throughout the research process by industry experts and scientists from Boehringer Ingelheim — one of the world’s leading pharmaceutical companies — as well as Yale’s world-class researchers and scholars. Fellowship training begins Sept. 1.
“This collaboration with Boehringer Ingelheim creates a world-class data science fellowship program that will drive development of novel methods and tools to analyze and interpret the many large and complex biomedical datasets that have been created in recent years,” said Yale School of Public Health Professor of Biostatistics, Genetics, Statistics, and Data Science Hongyu Zhao, PhD, principal investigator for the project.
The program will be based at the Yale Center for Biomedical Data Science (CBDS) in New Haven, Connecticut. The center is an essential part of a growing data science hub at Yale University, which has identified integrated data science as one of its primary investment areas over the next decade. CBDS is located within Yale School of Medicine and currently supports more than 100 faculty members and researchers representing such disciplines as bioinformatics, modeling, statistics, computer science, artificial intelligence, mathematics, biology, precision medicine and public health.
“In partnering with a top-tier academic and research institution like Yale, we aim to recruit and train a new generation of highly skilled data scientists to help us accelerate development of novel treatments and therapies for human disease and improve health outcomes for our patients,” said Jan Nygaard Jensen, PhD, Global Head of Computational Biology and Digital Sciences at Boehringer Ingelheim.
The partnership reflects a mutual vision between Boehringer Ingelheim and Yale University. It is part of a comprehensive strategic program at Boehringer Ingelheim which will harness the power of data science to transform drug discovery and development. The aim is to catalyze the next breakthrough therapies that change lives by accelerating timelines, improving scientific and clinical success and further elevating patient centricity.
“Boehringer Ingelheim is pleased to build upon our successful relationships with Yale to foster the next generation of scientists and harness the power of data science to bring our vision of making new and better medicines for patients in need,” said Clive R. Wood, PhD, Senior Corporate Senior Vice President, Global Head, Discovery Research, Boehringer Ingelheim. “We believe our shared ambition and outlook will build a world-class data science community to attract outstanding researchers and work to achieve breakthroughs that patients need.”
Initially the program will award as many as three competitive fellowships per year, up to a total of nine over the first five years. In addition to receiving research funding and mentorship, program fellows will be invited to participate in campus and corporate visits, networking events and annual symposia.
A joint selection committee comprising representatives of Yale and Boehringer Ingelheim will set annual data-driven research themes for the program. These themes may include such topics as genomic analysis, biomarkers, data-driven therapeutic research, medical image informatics, precision medicine and translational medicine. The selection committee will consider proposed research projects’ alignment with prioritized themes in judging submissions and post-doctoral applicants.
Yale’s data science ecosystem is supported by a host of cutting-edge research institutions working collaboratively. In addition to CBDS, they include Yale’s Systems Biology Institute, Center for Mendelian Genomics, Center for RNA Science and Medicine, and Center for Medical Informatics. Yale’s biobanks and technology core include: the Yale BioBank GENERATIONS,VA Million Veteran Program, Center for Research Computing, Center for Genomic Health, and Center for Genomic Analysis, which houses the ninth largest genomic library in the world.
Xinxin (Katie) Zhu, MD, PhD, executive director of the Yale Center for Biomedical Data Science, said the fellowship program offers an exciting opportunity for the development of innovative data-driven approaches for different medical conditions that can be translated from the lab to the patient’s bedside. It is an especially opportune time, she said.
“The vast amount of biomedical data being generated today has created a tremendous need for highly skilled data scientists who can use this information to advance care,” said Zhu.
Specialists in biomedical data science and health informatics can identify statistical associations and patterns of disease. They also can develop complex machine learning models and simulations of molecular, cellular and organismic systems to increase the probability of clinical success through precision medicine and other methods.
“This helps clinicians and pharmaceutical companies such as Boehringer Ingelheim identify potential new pathways for treatment and eradication of disease,” Zhu said.
To apply for a Yale-Boehringer Ingelheim Biomedical Data Science Fellowship, please go to https://medicine.yale.edu/cbds/bdsfellowship.
Please click on the following link for ‘Notes to Editors’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Colin Poitras: firstname.lastname@example.org, +1 860.301.6440
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
deWiz Making a Buzz After Closing out Series-A Funding With More Than 5 Million USD Investment21.6.2021 15:33:00 CEST | Press release
After more than five years of development, deWiz’s new wearable technology is going to market after closing out its Series-A funding round with more than 5M USD in new investment. The funding will fuel deWiz’s go-to-market launch strategy with a robust marketing plan, staffing to support growth and resources to ensure a healthy supply chain. Additionally, investment was synced with a new composition of the board of directors for deWiz, including Chairman of the Board, CEO and co-founder Christian Bergh; CTO and co-founder Markus Westerberg; World Golf Hall of Fame and business entrepreneur Annika Sörenstam; Newton Aguiar; and Erik Näsström. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005497/en/ deWiz wearable tech, a new golf training aid that helps golfers swing, feel and improve more quickly by providing instantaneous feedback via an electric pulse. (Photo: Business Wire) The science behind deWiz minimizes the gue
Membership Collective Group Announces Filing of Registration Statement for Proposed Initial Public Offering21.6.2021 15:32:00 CEST | Press release
Membership Collective Group (“MCG”), a global membership platform comprised of Soho House, Soho Works, The Ned, Scorpios Beach Club and Soho Home, and related digital platforms, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. MCG has applied to list its Class A common stock on the New York Stock Exchange under the ticker symbol “MCG”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005494/en/ Soho House New York (Graphic: Business Wire) J.P. Morgan and Morgan Stanley will serve as joint lead book runners for the proposed offering. Goldman Sachs & Co. LLC, BofA Securities and HSBC will be joint book runners. Citibank will serve as a co-manager. The
American Express Plans Live Audio Webcast of Second Quarter 2021 Earnings Conference Call21.6.2021 15:30:00 CEST | Press release
American Express Company (NYSE: AXP) plans to host a live audio webcast of its earnings conference call at 8:30 a.m. (ET) on Friday, July 23, 2021, to discuss second quarter 2021 financial results. The webcast will be accessible to the general public through the American Express Investor Relations website at https://ir.americanexpress.com/. The financial results and presentation materials are scheduled to be released and posted on the website at approximately 7 a.m. (ET) prior to the conference call, and an audio replay will be available on the website following the call. ABOUT AMERICAN EXPRESS American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress. Vie
The Blood Center of New Orleans Cooperates With Biolog-id to Enhance Visibility, Availability, and Traceability of Life-saving Blood Components21.6.2021 15:17:00 CEST | Press release
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with The Blood Center of New Orleans. Biolog-id’s cutting-edge technology will provide digital visibility to all platelet types in accordance with the new FDA bacterial risk control guidance. The biolog-id solution will support operational, distribution and planning decisions across the entire lifecycle of these strategically important products. The use of the biolog-id solution for the rare red blood cells inventory will streamline the management of this complex inventory, facilitating better internal cooperation and optimizing the fulfilment of customer orders. “We are firm believers in leveraging technology to improve the efficiency, quality, and safety of the blood supply,” said Billy Weales, President & CEO at The Blood Center. “Our cooperation with biolog-id allows us to achieve these goals with two of our most critical blood components – platelets and rare red blood
Sky Labs Finalizes Series B Round Successfully Planning to Take Over Global Markets21.6.2021 15:00:00 CEST | Press release
Attracting USD 20 million investment, Sky Labs (CEO: Jack Lee), a global health care start-up, finalized Series B Round successfully. The accumulated amount of investment Sky Labs has attracted is USD 30 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005004/en/ Sky Labs, a global health care start-up, finalizes Series B Round successfully attracting USD 20 million investment. The accumulated amount of investment is USD 30 million. Sky Labs developed CART-I, the world’s first AI-based ring-type heart monitoring platform. It consists of a ring-type wearable medical device and user’s application and medical professional’s web platform and enables atrial fibrillation patients to conduct monitoring when they are not in a hospital. In addition, the photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger to measure irregular pulse waves. The measured data are transmitted to a cloud platfo
Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine21.6.2021 14:01:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied. Prevalence rates were positively associated with the socio-economic status of the geographic area studied, suggesting that those living with migraine from less advantaged areas may find it harder to achieve an accurate diagnosis and thereby access appropriate therapy. “These findings are concerning not least because they suggest significant ‘migraine awareness inequity’ in this population,” said Professor Gal Ifergane, study investigator, practitioner, head of the Depart
New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congress21.6.2021 14:01:00 CEST | Press release
A new analysis presented by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on AJOVY® (fremanezumab) injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular events. The data, drawn from an analysis of three published Phase 3 studies of fremanezumab and presented at the 7th Congress of the European Academy of Neurology (EAN), showed minimal changes in the heart rate and blood pressure of those patients studied over a 12 week period. 1 “As a CGRP inhibitor, fremanezumab has been shown to provide protection against migraine in suitable patients, and we remain focused on continued assessment of the safety profile of this therapy, particularly in relation to heart-related issues as it is believed CGRP itself acts as a ‘safeguard’ during cardiovascular ischemia and other events,” said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Mi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom